With a proven ability to develop 3-D protein structures of X-ray crystallographic quality, SBI has a developed a powerful technology protocol for efficient, well-focused drug discovery. Converting in silico hits to drug candidates relies upon a combination of SBI's expertise in computer-aided drug design, medicinal chemistry, cell biology, biochemistry, and pharmacology, coupled with experienced leadership, intuition, and a strong track record of success.

SBI employs proprietary DynaPharm® and CombiLib® in silico screening technologies to rapidly generate drug leads for pharmaceutical and biotech corporate partners. DynaPharm® templates are virtual constructs, derived from dynamic simulations of the changes in flexible protein shape and the molecular characteristics of likely drug leads. CombiLib® technology unlocks combinatorial chemistry space, making it possible to computationally search and screen public or private databases of drug-like compounds with great speed and efficiency. With SBI's Lead Discovery program, numerous compounds from diverse chemical classes can be computationally tested to narrow the list of appropriate and effective compounds, thereby providing a more reasonable number of starting points for lead optimization and the foundation for broad, composition-of-matter patent coverage. The process typically yields active initial drug leads in 60-120 days, and can be validated with wet chemistry.

 

Benefits Include:

• Enables immediate use of protein structural information in structure-based drug design and discovery

• Dramatically reduces screening cost and time

• Reduces compound synthesis and acquistion costs approximately 100-1,000 fold

• Increases probability of identifying molecules with greater specificity

• Enables rapid identification and analysis of structurally-related protein targets for the design of highly selective drug candidates

• Harnesses, in a practical manner, the full range of molecular diversity promised by combinatorial chemistry